Primary outcome | ||||||
---|---|---|---|---|---|---|
Mean (mm VAS, 6th week of treatment) | Test of fixed effects | |||||
VOC | 95% CI | Difference | 95% CI | F-value | P-value (r >F) | |
Betamethasone | 9.10 | 5.31 to 12.88 | 0.56 | −2.88 to 3.99 | 0.11 | 0.744 |
Placebo | 8.54 | 4.75 to 12.33 | ||||
Arm 1 | 10.31 | 5.82 to 14.79 | 2.98 | −3.78 to 9.74 | 0.81 | 0.376 |
Arm 2 | 7.33 | 2.28 to 12.38 | ||||
Temperature | 6.24 | 0.018 |
Secondary outcome | ||||||
---|---|---|---|---|---|---|
Mean (mm VAS, 6th week of treatment) | Test of fixed effects | |||||
VOD | 95% CI | Difference | 95% CI | F-value | P-value (r >F) | |
Betamethasone | 5.07 | 2.37 to 7.77 | 0.88 | −2.22 to 3.98 | 0.33 | 0.567 |
Placebo | 4.19 | 1.49 to 6.89 | ||||
Arm 1 | 5.57 | 2.63 to 8.51 | 1.88 | −2.56 to 6.31 | 0.74 | 0.396 |
Arm 2 | 3.69 | 0.38 to 7.00 | ||||
Temperature | 0.88 | 0.357 |
Arm 1 = betametasone + placebo. Arm 2 = placebo + betametasone. VAS = visual analogue scale. VOC = visual analogue scale on complaints. VOD = visual analogue scale on disability.